BioAge Labs director granted 22,000 stock options
BioAge Labs, Inc. director Patrick G. Enright received a grant of stock options covering 22,000 shares of common stock.
Rhea-AI Filing Summary
BioAge Labs, Inc. director Patrick G. Enright received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $15.48 per share and were awarded as compensation rather than purchased in the open market.
These options vest in full on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as Enright continues to serve the company through that vesting date. Following this grant, he holds 22,000 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 22,000 shares
Grant/Award
1 txn
Insider
ENRIGHT PATRICK G
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 22,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 22,000 contracts (Direct)
Footnotes (1)
- F1. The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.
Key Figures
Options Granted: 22,000 options
Exercise Price: $15.48 per share
Underlying Shares: 22,000 shares
+2 more
5 metrics
Options Granted
22,000 options
Stock Option (Right to Buy) granted to director
Exercise Price
$15.48 per share
Conversion or exercise price of granted options
Underlying Shares
22,000 shares
Common stock underlying the option award
Post-Grant Option Holdings
22,000 options
Total options following transaction
Option Expiration
June 9, 2036
Expiration date of the stock option award
Key Terms
Stock Option (Right to Buy), Common Stock, exercise price, grant date, +2 more
6 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: "15.4800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
grant date financial
"the one year anniversary of the grant date, subject to the reporting person's continued service"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
annual meeting of the Issuer's stockholders financial
"the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders"
vesting financial
"The entire option award shall vest on the earlier of the next annual meeting or the one year anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BioAge Labs (BIOA) report for Patrick G. Enright?
BioAge Labs reported that director Patrick G. Enright received a grant of stock options for 22,000 shares of common stock. This was a compensation-related award, not an open-market purchase or sale, and is recorded as a derivative security on the Form 4.
What is the exercise price of Patrick Enright’s BioAge Labs (BIOA) stock options?
The granted stock options have an exercise price of $15.48 per share. This means Enright can buy up to 22,000 shares of BioAge Labs common stock at that fixed price once the options are vested and exercised, regardless of the future market price.
How many BioAge Labs (BIOA) stock options does Patrick Enright hold after this filing?
After this grant, Patrick Enright holds stock options for 22,000 shares of BioAge Labs common stock. These are shown as directly owned derivative securities, reflecting his position if he later exercises them at the stated strike price.
When do Patrick Enright’s BioAge Labs (BIOA) stock options vest?
The option award vests entirely on the earlier of the next annual meeting of BioAge Labs’ stockholders or the one-year anniversary of the grant date. Vesting is conditional on Enright’s continued service to the company through the applicable vesting date.
What is the expiration date of Patrick Enright’s BioAge Labs (BIOA) stock options?
The stock options granted to Patrick Enright expire on June 9, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase BioAge Labs common stock at the $15.48 exercise price.
Was Patrick Enright’s BioAge Labs (BIOA) transaction a buy or a sale of stock?
The transaction was neither a traditional buy nor sale in the market. It was a grant of stock options as compensation, coded as a grant or award acquisition, giving Enright the right to purchase shares later at the fixed exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
